Targeted Bisulfite Sequencing-Based Analysis of MGMT Promoter Methylation in Meningiomas

DOI QR Code

Bujko, Mateusz (Department of Molecular and Translational Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology) ;
Kober, Paulina (Department of Molecular and Translational Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology)

Supported by : National Science Centre

Chamberlain MC, Tsao-Wei DD, Groshen S (2004). Temozolomide for treatment-resistant recurrent meningioma. Neurology, 62, 1210-2. https://doi.org/10.1212/01.WNL.0000118300.82017.F4
Dullea A, Marignol L (2015). MGMT testing allows for personalised therapy in the temozolomide era. Tumor Biol, 37, 87-96.
Hegi ME, Diserens A-C, Gorlia T, et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 352, 997-1003. https://doi.org/10.1056/NEJMoa043331
Herman JG, Graff JR, Myohanen S, et al. (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci, 93, 9821-6. https://doi.org/10.1073/pnas.93.18.9821
Larijani L, Madjd Z, Samadikuchaksaraei A, et al. (2014). Methylation of O 6 -methyl guanine methyltransferase gene promoter in meningiomas - comparison between tumor grades I , II , and III. Asian Pac J Cancer Prev, 15, 33-8. https://doi.org/10.7314/APJCP.2014.15.1.33
Lee EJ, Luo J, Wilson JM, et al. (2013). Analyzing the cancer methylome through targeted bisulfite sequencing. Cancer Lett, 340, 171-8. https://doi.org/10.1016/j.canlet.2012.10.040
Masser DR, Stanford DR, Freeman WM (2015). Targeted DNA methylation analysis by next-generation sequencing. J Vis Exp, 96, 1-11.